Our Company

Theseus Pharmaceuticals™

At Theseus, we are passionately committed to improving the lives of cancer patients by working to outsmart cancer resistance. Resistance mutations limit the efficacy of existing targeted therapies, and present a critical challenge in cancer treatment today.

Our approach is to develop “pan-variant” targeted therapies that address all known drug resistance mutations. Led by a team of pioneers in the discovery and development of tyrosine kinase inhibitors (TKIs), we believe these next-generation, pan-variant kinase inhibitors are the only way to address cancer resistance.

The potential benefit of truly pan-variant inhibitors is two-fold: they effectively inhibit resistance mutations that have emerged on prior therapies, and they may also suppress the emergence of mutations when used in earlier lines of therapy.
Existing TKIs are limited in their efficacy due to the emergence of resistance mutations. Using our structure-guided drug design with predictive screening methodologies, we believe we can design TKIs that target all known mutations.

With decades of experience developing and commercializing effective targeted cancer therapeutics, our team draws on its deep expertise to drive towards our goal of delivering safe, effective treatments that provide durable responses for people living with cancer.